There is no generally accepted human international reference preparation for ACTH. The different centres offering clinical ACTH measurement therefore select assay standards from the limited range of human-purified and synthetic preparations currently available. We have examined the relative potencies of three synthetic ACTH standards in comparison with the NIBSC humanpurified 1-39 (code 74/555) in a two-site immunoradiometric assay (IRMA) for ACTH. All of the standards produced parallel curves in the IRMA but there was a wide variation in potency between the preparations giving highly significant differences in quality control and patients' ACTH results. Standards supplied by the National Hormone and Pituitary Programme, Bachem UK Ltd and Universal Biologicals Ltd gave lower ACTH results than results calculated using the NIBSC preparation. The potency differences between these standards emphasise the need for a reference preparation and, in the meantime, the necessity to define normal reference ranges for each laboratory.
With the advent of monoclonal antibodies to ACTH,l two-site immunoradiometric assays (IRMAs) can be developed more easily2.3. and may well supersede radioimmunoassays because of their improved precision, accuracy and reliability. As this technically simple assay becomes more widely used, interest in ACTH measurement may increase, and problems are likely to arise due to the absence of an international reference preparation for human ACTH, upon which to base assay standardisation.
Presently, different laboratories obtain their ACTH standard preparations from one or two research standards or from commercially available preparations and these include both humanpurified and synthetic ACTH. Bangham" has outlined the problems involved in the selection of standards and concludes that preparations should be (a) of correct molecular form, (b) stable, (c) characterised by physical, chemical, biological and immunochemical methods, (d) of assigned numerical value, and (e) identical for each sample. It appears to be difficult to meet these criteria with human-purified ACTH prep-·Present address: Technical Production, Unipath Oxoid Ltd, Norse Road, Bedford MK41 009, UK.
Correspondence: A White. 96 arations, although there are several human synthetic ACTH peptides available which would initially appear to overcome these problems of purity. However, synthetic pep tides are constructed in a stepwise manner and at each reaction stage efficiency is less than 100%: intermediate synthesis products or 'error peptides' therefore accumulate and result in heterogeneity of these synthetic preparations.
The difficulties involved in standardisation, as described, are common to many biological substances, and would ideally be overcome in this case by the existence of an international reference preparation for human ACTH which meets Bangham's criteria. In the absence ofa reference, it is essential that different centres measuring ACTH become aware of the potency differences between the ACTH preparations currently available. In this study we have examined four ACTH preparations, the human-purified ACTH standard supplied by the National Institute of Biological Standards and Control (NIBSC), code no. 74/555, the synthetic ACTH standard supplied by the National Hormone and Pituitary Programme (NHPP) (formerly the National Pituitary Agency) and two synthetic ACTH preparations purchased from Bachem UK Ltd and Universal Biologicals Ltd. The performance of these stan-dards has been compared in a two-site immunoradiometric assay developed in this laboratorywhich measures ACTH 1-39 but does not detect the fragments ACTH 1~13 or 18-39. We have assessed the potency differences of these preparations and evaluated the implications for clinical diagnosis arising as a result of these differences.
Materials and Methods

REAGENTS
Heat-inactivated horse serum, sheep serum, and bovine serum albumin (BSA) were purchased from Wellcome Diagnostics (London, UK), the Scottish Antibody Production Unit (Glasgow, UK), and Miles Laboratories Ltd (Slough, UK) respectively. Tween-20 and Triton X100 were supplied by Sigma Chemical Co. (Poole, UK). Ancillary chemicals of Analar grade were purchased from BDH (Poole, UK). Polystyrene assay tubes (75 x 33 mm) were obtained from Basildon Mouldings (Basildon, UK). STANDARDS NIBSC, human-purified ACTH 1-39, code 74/ 555,6'2 IU/25 Jlg was supplied by NIBSC, South Mimms, UK. This preparation is in short supply and is not yet fully characterised." The NHPP standard, synthetic ACTH 1-39,4'71 IU/50 ug, was supplied by the National Hormone and Pituitary Programme (formerly National Pituitary Agency), University of Maryland School of Medicine, Baltimore, Maryland, USA. Both this standard and the NIBSC preparation are calibrated against the 3rd International Standard for ACTH (a porcine preparation).
The Bachem preparation, synthetic ACTH 1-39, 500 ug, was purchased from Bachem UK Ltd, Saffron Walden, UK. The UBL standard, synthetic ACTH 1-39, 500 ug, was purchased fron Universal Biologicals, London, UK. Neither of the standards supplied by Bachem and UBL is calibrated against the 3rd International Standard for ACTH.
STANDARD PRE PARA nON
With the exception of the NHPP standard, the ACTH preparations were dissolved in 0·9% NaCl, 0·5% BSA, adjusted to pH 3·5 with 0·1 M HCJ:5 the former was reconstituted in 0·01 M HCl as directed. Standards were diluted to 4 Jlg/mL in assay diluent (0,1 mol/L P0 4 , pH 7-4, with 0·02%
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w]» sodium azide and 0·5% w/v BSA), and then further diluted to give working standards of 5000 ng/L, To examine between-batch variation in working standards, three batches of the 5000 tig] L standard were diluted from the 4 Jlg/mL stock solution for each ACTH preparation studied. Standards were aliquoted (0'5 mL), flash frozen and stored at -70°C according to Lambert et al? To assess each standard in the ACTH IRMA an aliquot of working standard (5000 ng/L) was diluted in assay buffer containing 10% vlv horse serum to give ACTH concentrations between 5 and 5000 ng/l; TWO-SITE IRMA PROTOCOL Preparation of radioiodinated monoclonal antibody lA12, coupling of monoclonal antibody 2A3 to Sephacryl S300 and optimisation of the IRMA are described by Dobson et al? 12SI antibody lAl2 was diluted in assay buffer (0,1 mol/L P04, pH 7-4, with 0·02% w/v sodium azide and 0·5% w}» BSA) containing 0·5% vlv normal sheep serum to saturate antibodies to ruminant immunoglobulins. Using a sequential addition protocol, standards (100 JlL) were incubated with 12SI antibody lAl2 (100 JlL, 100,000 cpm containing approximately 24 ng) overnight at 4°C, and then solid-phase antibody 2A3 (100 JlL of a 5% slurry) was added and shaken on a Sucroagitator (Boots-Celltech Diagnostics Ltd, Slough, UK) for 2 h at room temperature. ACTH bound to the solid-phase antibody was separated by the method of sucrose layering using a two-pass system." Tubes were counted for 3 min in a LKB multi-well gamma counter, model 1260 (LKB Instruments, South Croydon, UK).
ASSESSMENT OF STANDARD PREPARATION
Each batch of each ACTH standard was assayed three times to give a total of nine assays for each standard preparation. During the study one batch of solid phase antibody 2A3 and three batches of labelled antibody lAl2 were used.
Potency differences between the ACTH preparations were assessed by reference to a set of quality control plasmas (QCs), prepared as previously described) to give theoretical final ACTH concentrations of25, 100,500 and 1000 ng/L, and by assay of plasma samples from three patients, denoted PI, P2 and P3.
DATA ANALYSIS
Standard preparation, batch, between-and within-assay variation was compared by analysis of variance for each of the QC and patient's samples. Using an optimised two-step protocol for the ACTH IRMA, the NIBSC preparation gave the least sensitive standard curve (mean zero ACTH ±2·5 x SD=4·7 ±2·5 ng/L, n=9). The mean background response at zero ACTH concentration was 79 cpm, with a doubling of counts at < 8·9 ng/L, The average responses at 5 x 10 3 ng/L were 20,000, 19,000, 25,000 and 26,000 cpm for the NIBSC, NHPP, Bachem and UBL standards respectively, to give signal-to-background ratios of between 240 and 329.
Results
RELA TIVE POTENCIES OF THE
ACTH STANDARDS
Typical standard curves obtained with the different ACTH preparations in the IRMA are shown in Fig. 1 . Analysis of variance reveals significant differences (P<O'OOI) greater than the assay-toassay or batch-to-batch variation between the UBL and Bachem preparations as compared with the NIBSC and NHPP standards. Based on these results, the most potent of the four standards studied is the UBL preparation. The Bachem preparation is the next most potent standard: the NIBSC and NHPP preparations are of similar potency but lower than both the UBL and Bachem standards. These differences are such that for a sample giving 1000 cpm in the IRMA, the ACTH concentration could be 50, 58, 92 or 106 ng/L when read off from the UBL, Bachem, NIBSC and NHPP standard curves respectively ( Fig. I) . The mean ACTH results calculated from each batch of the four standards are shown in Table I . For the NIBSC, Bachem and UBL preparations the batch-to-batch variation was less than the assay-to-assay variation. Assay results obtained with batch I of the NHPP standard were outside the laboratory reference ranges calculated and would have been discounted in a clinical assay. Inclusion of these batch data resulted in a significant difference (P < 0,001) between batches of this standard, and results from this batch are therefore excluded from further analysis. PI  168  162  158  185  138  150  98  86  94  81  72  78  P2  173  188  163  195  168  152  100  101  97  81  80  80  P3  296  303  303  333  271  287  172  158  175  143  140  150 Each result represents the mean of 3 assays with duplicate samples. Each result represents the mean of 9 assays for NIBSC, Bachern and UBL and 6 assays for NHPP.
ASSA Y PRECISION
The mean ACTH results and coefficients of variation (CV) calculated over nine assays for the NIBSC, Bachem and UBL standards, and over six assays for the NHPP standard are shown in Table 2 . The mean coefficient of variation for all the quality control samples and patient samples was lowest with the Bachem standard (7'5%), with the NIBSC standard giving 8·2%, the NHPP standard 9·0% and the UBL standard 9·5%. This precision was achieved even though three different batches of the 125I-labelled monoclonal antibody were used for the different assays.
PA TIENT RESULTS
Significant differences were obtained for both the QC and patients' plasmas as a result of the differences in potency between the four standard preparations. The more potent the standard is, the lower the results obtained for QC and patient samples. For example, ACTH levels for patient 3 calculated from the NIBSC standard curve are 2'1, 1·8 and 1·1 times higher than those calculated using the UBL, Bachem and NHPP curves respectively. In Table 3 , the ACTH levels calculated from the NHPP, Bachem and UBL standard curves are expressed as a percentage of the concentration derived using the NIBSC curve. The differences observed are consistent over the working range of the IRMA for all the standard preparations indicating parallelism of all of the standard curves.
Discussion
Four human ACTH preparations were selected for assessment as suitable standards in the two- PI  163  89  57  47  P2  175  91  57  46  P3  301  93  56  48 Resultscalculatedfrom meanof threeassaysfor each of three batches with NIBSC, Bachemand UBL and two batches for NHPP. site IRMA. The purified ACTH preparation from NIBSC has the advantage of lack of variation between ampoules but the disadvantage of being in short supply and of not being totally characterised (in terms of impurities). The synthetic ACTH preparation from NHPP is not as easily obtainable, but like the NIBSC standard has been assigned a numerical value for biological content (international units) as calibrated against the 3rd International Standard for corticotrophin, a porcine preparation itself shown to contain certain impurities. The two commercially available synthetic ACTH preparations have the advantage of purity, but the possible disadvantage of error peptides. In addition they are not calibrated against an international standard for ACTH and
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can only be defined in terms of mass which gives certain inherent problems (vide infra). The four ACTH standards showed significant differences in potency when used routinely in the two-site IRMA. These differences were greater than the assay-to-assay or batch-to-batch variation and were therefore due to the standards themselves. Although the international unit values assigned to the NIBSC and NHPP preparations differ significantly, 12·4 IV/50 /lg and 4·7 IV/50 /lg respectively, being approximately threefold higher for the NIBSC standard, the potencies of the two standards in the ACTH IRMA are similar. The Bachem and VBL preparations can only be compared with each other, and with the NIBSC and NHPP standards on the basis of weight, as they are not calibrated against an international standard. The results obtained indicate that the VBL standard is the most potent and the NHPP standard least potent with a two-fold difference in potency between them.
Weighing error is one of a number of factors affecting the relative potencies ofthe preparations studied here. The standards were all diluted from an assigned mass to give a concentration of 4 /lg/ mL, thus assuming the exact amount of material in an ampoule to be 25, 50, 500 and 500 ug for the NIBSC, NHPP, Bachem and VBL preparations respectively. Following persistent enquiries, Bachem gave an estimate of weighing error (± 5% on 500 /lg). VBL were unable to provide the information but an error of equal magnitude is likely and, given that the amount of material involved is smaller, the margin of error for the NIBSC and NHPP standards may be larger still.
When comparing these standards one must consider the total peptide content and the purity of synthetic ACTH preparations. When standards were purchased from Bachem and VBL, neither company supplied information regarding the peptide content of their products; therefore the two standards were assessed on the assumption that all of the material received was ACTH 1-39. Later, on repeated enquiries, Bachem provided an analysis of their synthetic ACTH which indicated a peptide content of 80%, the remainder being trifluoroacetic acid and water. This recent information implies that the Bachem ACTH preparation is in fact more potent than we have shown. The difference between this standard and the NIBSC and NHPP preparations is therefore greater than indicated here. The VBL catalogue states a peptide content of 95% for all products but this could not be confirmed for ACTH on enquiry. Even when peptide content is known accurately, a small proportion will consist of 'error peptides' which are undetectable by normal analytical methods.
The difficulties described here, caused by the absence of an international reference preparation for human ACTH, can only be counteracted by acknowledging the potency differences between the available ACTH standards and taking these differences into account when comparing ACTH results with those of other centres. The potencies of the standards discussed will vary with the specificities of the antibodies or antisera used, and also with the type of assay in which these are employed. It is therefore necessary for each centre measuring ACTH to define the standard to be used in its own particular assay system and to set a normal reference range for the assay according to this preparation. With the two-site immunoradiometric assay, differences in potency become significant for clinical diagnosis when, for example, a patient's ACTH levels are within the normal range when calculated from the Bachem standard curve, but classified as pituitary-dependent Cushing's disease if determined from a NIBSC standard curve.
For development of the two-site immunoradiometric assay, the NIBSC standard preparation was originally chosen because of the guaranteed consistency between ampoules and for comparison with an in-house radioimmunoassay based on the method of Nicholson et al. ' The normal reference range for the two-site IRMA was therefore defined as 5-50 ng/L with the NIBSC standard. As we have most experience with the NIBSC human-purified ACTH preparation in our assay system, we will continue to use this standard until an internationl reference preparation for human ACTH is established or until a commercial company can provide a more suitable ACTH preparation with defined specifications.
